


## TFBS Biosciences expands state-of-the-art facility for viral vector production in Taiwan

15 July 2022 | News

TFBS to collaberate with Univercells Technologies to leverage flexible and scalable viral production using scale-X<sup>™</sup> carbo mid-scale fixed-bed bioreactor



TFBS Bioscience Inc., the leading GMP viral vector contract development and manufacturing organization in the Asia-Pacific region providing the first viral vector manufacturing in Taiwan, is announcing a partnership with Univercells Technologies, a leading provider of novel biomanufacturing technologies for flexible and scalable viral production.

TFBS will leverage the scale-X<sup>™</sup> carbo mid-scale fixed-bed bioreactor from Univercells Technologies for good manufacturing practice (GMP) viral vector operations at the expanding state-of-the-art New Taipei City facility.

The full scale-X bioreactor portfolio includes the hydro for small-scale benchtop and research applications; carbo for process development, clinical and scalable commercial phases, which will be leveraged in this partnership; and nitro for large-scale commercial production.

TFBS manufactures viral vectors, including Adeno-Associated Virus (AAV), Lentivirus (LV), Adenovirus (Adv), Retrovirus (RV), and custom vectors for research/preclinical or clinical studies (GMP-compliant, up to phase II) use.

The team is currently working to deliver a one-stop service approach, building comprehensive QC testing for viral vectors and related biological safety testing services into the onsite offer at the expanding New Taipei City facility. And construction is soon to be underway for the addition of a new GMP-grade manufacturing facility for viral vectors expected to be online in 2024.